P2RY12 and myocardial infarction: Our meta-analysis showed that single antiplatelet therapy (aspirin or P2Y12 inhibitors) in ACS has the highest embolism risk and poorest efficacy, while NOAC monotherapy carries a notable myocardial infarction risk.